Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 5/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | BAD | Q92934 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003226 | 0.98 | TSHR (0.50) | TSHRNOS3NOS1NOS2ACHE | |
| SCHEMBL5604 | 0.93 | TSHR (0.48) | TSHRNOS3NOS1NOS2ACHE | |
| Bromide SCHEMBL11831501 | 0.91 | TSHR (0.46) | TSHRNOS3NOS1NOS2ACHE | |
| SCHEMBL27008 | 0.83 | — | — | |
| SCHEMBL24141454 | 0.77 | TSHR (0.46) | TSHRNOS3NOS1NOS2ACHE | |
| SCHEMBL14999656 | 0.73 | TSHR (0.52) | TSHRNOS3NOS1NOS2ACHE | |
| SCHEMBL7449194 | 0.72 | SIGMAR1 (0.57) | TSHRACHECHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL7019855 | 0.72 | SIGMAR1 (0.57) | TSHRNOS3NOS1NOS2CHRNB4 | |
| SCHEMBL13281552 | 0.71 | TSHR (0.30) | TSHR | |
| SCHEMBL7344549 | 0.71 | CD44 (0.45) | MAPTMAOBMEN1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 645 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2023-05-18 | — | — | US | claimed |
| EP-4110765-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | Board of Regents, The University of Texas System (US) | 2023-01-04 | — | — | EP | claimed |
| US-11535647-B2 | Peptide purification method using sulfonate compound | NAGASE & CO., LTD. (JP) | 2022-12-27 | — | — | US | claimed |
| US-20220144888-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | NAGASE & CO., LTD. (JP) | 2022-05-12 | — | — | US | claimed |
| EP-3851446-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | Nagase & Co., Ltd. (JP) | 2021-07-21 | — | — | EP | claimed |
| US-20210069188-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2021-03-11 | — | — | US | claimed |
| US-10689394-B2 | Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof | THE UNIVERSITY OF TOKYO (JP) | 2020-06-23 | — | — | US | claimed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | claimed |
| EP-3630770-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | Relay Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | claimed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | claimed |
| EP-0552489-B1 | Peptide, production and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-03-04 | — | — | EP | claimed |
| WO-1997027199-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-07-31 | — | — | WO | claimed |
| US-5614497-A | TREATMENT OF HYPERTENSION, CARDIOVASCULAR DISEASE AND RENAL DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-03-25 | — | — | US | claimed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | claimed |
| EP-0552489-A2 | Peptide, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | claimed |
| US-4914092-A | ANTIULCER AGENTS | SYNTHELABO (FR) | 1990-04-03 | — | — | US | claimed |
| US-4638000-A | HYPOTENSIVES, ANGIOTENSIN INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-01-20 | — | — | US | claimed |
| US-4548932-A | ANGIOTENSIN INHIBITOR, HYPOTENSIVE AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-22 | — | — | US | claimed |
| EP-0077983-A1 | Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-05-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | NQO2, NQO1, NDUFV2 | TSHR 4710/4885NOS3 619/4885NOS1 1109/4885 |
| US-10689394-B2 | Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof | BRD4, DRD4, TH | TSHR 379/4885NOS3 1357/4885NOS1 2128/4885 |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | TSHR 1884/4885NOS3 2077/4885NOS1 2809/4885 |
| US-20220144888-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | VIP, IAPP, RPS27A | TSHR 1129/4885NOS3 3103/4885NOS1 2918/4885 |
| US-11535647-B2 | Peptide purification method using sulfonate compound | VIP, IAPP, RPS27A | TSHR 1129/4885NOS3 3103/4885NOS1 2918/4885 |
| US-20210069188-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN2, PTPN5, PTPRJ | TSHR 2615/4885NOS3 2547/4885NOS1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.